Anvisa Approves New Drug: Price & Availability in Brazil (2026)

Cenobamate Approved in Brazil: New Hope for Severe Epilepsy Patients

São Paulo, Brazil – In a significant development for individuals battling severe forms of epilepsy, the Brazilian Health Regulatory Agency (Anvisa) has granted approval for cenobamate, a new anti-epileptic medication. The decision, announced earlier this month, offers a potential new treatment option for patients whose seizures remain uncontrolled despite existing therapies. While the approval marks a crucial step, the medication’s availability hinges on the subsequent pricing determination by the Câmara de Regulação do Mercado de Medicamentos (CMED), Brazil’s pharmaceutical pricing regulator, with anticipated commercialization later in 2026.

Epilepsy affects over 50 million people worldwide, according to the World Health Organization, and a substantial proportion of these individuals—approximately one-third—continue to experience seizures even with current medication regimens. This treatment resistance underscores the urgent demand for innovative therapies. Cenobamate represents a novel approach, working through a unique mechanism to enhance neuronal inhibition in the brain, thereby reducing seizure frequency.

Understanding Cenobamate’s Mechanism of Action

Cenobamate, developed by SK Life Science, is a derivative of amides, a class of compounds known for their anticonvulsant properties. Unlike many existing anti-epileptic drugs, cenobamate doesn’t solely target a single mechanism. It enhances the function of GABA-A receptors, a major inhibitory neurotransmitter system in the brain, and also blocks voltage-gated sodium channels, reducing neuronal excitability. This dual action is believed to contribute to its efficacy in controlling seizures. Clinical trials have demonstrated cenobamate’s ability to significantly reduce seizure frequency in patients with focal onset seizures, with or without secondary generalized seizures.

Anvisa’s Rigorous Approval Process

The approval by Anvisa follows a comprehensive review of clinical data submitted by Eurofarma, the company responsible for bringing cenobamate to the Brazilian market. Anvisa, the Brazilian equivalent of the U.S. Food and Drug Administration (FDA) or the European Medicines Agency (EMA), meticulously evaluates the safety and efficacy of all pharmaceutical products before granting market authorization. The agency’s stringent standards ensure that only medications meeting rigorous quality and performance criteria are available to the Brazilian population. Eurofarma maintains strict compliance with Good Manufacturing Practices (GMP) established by Anvisa, as evidenced by their certifications. Eurofarma’s commitment to quality is a key factor in securing regulatory approvals.

The Role of CMED in Price Regulation

With Anvisa’s approval secured, the next critical step involves the CMED’s determination of the maximum allowable price for cenobamate. The CMED plays a vital role in regulating the pharmaceutical market in Brazil, ensuring that medications remain accessible to patients. As outlined on Anvisa’s website, the CMED establishes both the Preço Máximo ao Consumidor (PMC) – the maximum price consumers can pay – and the Preço Máximo de Venda ao Governo (PMVG) – the maximum price for government purchases. The pricing process considers factors such as production costs, research and development expenses, and comparative pricing in other markets. The goal is to strike a balance between incentivizing pharmaceutical innovation and ensuring affordability for patients.

Impact on Epilepsy Patients in Brazil

The introduction of cenobamate has the potential to significantly improve the quality of life for many epilepsy patients in Brazil. For those who have exhausted other treatment options, cenobamate offers a new avenue for seizure control. However, access to the medication will depend heavily on its final price, as affordability remains a major barrier to healthcare for many Brazilians. The availability of specialized epilepsy centers and trained neurologists will also be crucial in ensuring that patients receive appropriate diagnosis and management with cenobamate.

What is the CMED and How Does it Work?

The Câmara de Regulação do Mercado de Medicamentos (CMED) is a multi-sectoral body responsible for establishing the rules for pricing and adjusting the prices of medications in Brazil. According to Eurofarma’s explanation of the CMED process, the agency’s decisions are based on a complex set of regulations designed to balance the interests of pharmaceutical companies, healthcare providers, and patients. The CMED’s pricing decisions are updated regularly to reflect changes in production costs, inflation, and market dynamics. The agency also considers the impact of pricing on access to essential medications.

Potential Side Effects and Monitoring

Like all medications, cenobamate can cause side effects. Common side effects reported in clinical trials include somnolence (drowsiness), dizziness, and fatigue. More serious, though less frequent, side effects may include mood changes, suicidal thoughts, and allergic reactions. Patients taking cenobamate will require careful monitoring by their healthcare providers to assess the medication’s effectiveness and manage any potential side effects. Regular blood tests may be necessary to monitor liver function and other parameters.

Looking Ahead: Commercialization and Access

Once the CMED establishes the maximum price, Eurofarma will be able to begin commercializing cenobamate in Brazil. The company has indicated that it anticipates launching the medication later in 2026. The initial rollout may focus on major urban centers and specialized epilepsy clinics. Efforts to expand access to cenobamate to patients in more remote areas will be crucial to ensure equitable healthcare access across the country. Patient advocacy groups and healthcare organizations will play a key role in raising awareness about cenobamate and advocating for its inclusion in public health insurance programs.

The approval of cenobamate represents a significant advancement in the treatment of severe epilepsy in Brazil. The coming months will be critical as the CMED determines the medication’s price and Eurofarma prepares for its launch. Continued monitoring of the medication’s effectiveness and safety, along with efforts to ensure equitable access, will be essential to maximizing its benefit to patients.

The next key milestone will be the CMED’s official announcement of the maximum price for cenobamate, expected in the coming months. Stay tuned to World Today Journal for further updates on this developing story.

Disclaimer: This article provides general information and should not be considered medical advice. Please consult with a qualified healthcare professional for any health concerns or before making any decisions related to your treatment.